Fumihiko Kakizaki
YOU?
Author Swipe
View article: Comprehensive Colorectal Cancer Stem Cell Transcriptomic Signatures That Can Predict Patient Prognostic Outcomes
Comprehensive Colorectal Cancer Stem Cell Transcriptomic Signatures That Can Predict Patient Prognostic Outcomes Open
Based on mRNA Expression Profiles of 57 Patient‐Derived Colorectal Cancer Stem‐Like Cell ( CRC ‐ SC ) Lines Compared With Normal Colonic Epithelial Stem‐Like Cells ( NCE ‐ SCs ), we Identified Five CRC Subtypes. The First Subtype of CRC ‐ …
View article: Monoclonal antibody for phosphorylated TRIO Y2681 that helps predict prognosis of post-operative colorectal cancer patients
Monoclonal antibody for phosphorylated TRIO Y2681 that helps predict prognosis of post-operative colorectal cancer patients Open
View article: Precision Oncology Framework Using Circulating Tumor Cells
Precision Oncology Framework Using Circulating Tumor Cells Open
Circulating tumor cells (CTCs) are multifaceted biomarkers with significant potential for precision oncology, offering opportunities to refine diagnoses and personalize treatments across various cancer types, including colorectal and breas…
View article: Novel and efficient method for culturing patient‐derived gastric cancer stem cells
Novel and efficient method for culturing patient‐derived gastric cancer stem cells Open
Experimental techniques for patient‐derived cancer stem‐cell organoids/spheroids can be powerful diagnostic tools for personalized chemotherapy. However, establishing their cultures from gastric cancer remains challenging due to low cultur…
View article: Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S1.
View article: Supplementary Figure S5 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S5 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Supplementary Figure S5
View article: Supplementary Figure S2 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S2 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S2 with its legend on page 2
View article: Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S1.
View article: Supplementary Figure S5 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S5 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Supplementary Figure S5
View article: Supplementary Figure S3 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S3 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S3 with its legend on page 2
View article: Supplementary Table S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Table S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Table S1.
View article: Supplementary Table S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Table S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Table S1.
View article: Data from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Data from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Recent advances in combinatorial chemistry led to the discovery of inhibitors targeting the KRAS G12C-mutant protein. However, efficacy of its monotherapy on colorectal cancer is limited. Thus, effective combination drugs should be explore…
View article: Supplementary Figure S2 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S2 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S2 with its legend on page 2
View article: Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S4 with its legend on page 2
View article: Supplementary Figure S3 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S3 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S3 with its legend on page 2
View article: Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S4 with its legend on page 2
View article: Supplementary Table S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Table S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Table S1.
View article: Data from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Data from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Recent advances in combinatorial chemistry led to the discovery of inhibitors targeting the KRAS G12C-mutant protein. However, efficacy of its monotherapy on colorectal cancer is limited. Thus, effective combination drugs should be explore…
View article: Data from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Data from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Recent advances in combinatorial chemistry led to the discovery of inhibitors targeting the KRAS G12C-mutant protein. However, efficacy of its monotherapy on colorectal cancer is limited. Thus, effective combination drugs should be explore…
View article: Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S4 with its legend on page 2
View article: Supplementary Figure Legends from Promotion of Colorectal Cancer Invasion and Metastasis through Activation of NOTCH–DAB1–ABL–RHOGEF Protein TRIO
Supplementary Figure Legends from Promotion of Colorectal Cancer Invasion and Metastasis through Activation of NOTCH–DAB1–ABL–RHOGEF Protein TRIO Open
Supplementary Figure Legends S1-S5
View article: Supplementary Figure S2 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S2 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S2 with its legend on page 2
View article: Supplementary Figure S3 from Promotion of Colorectal Cancer Invasion and Metastasis through Activation of NOTCH–DAB1–ABL–RHOGEF Protein TRIO
Supplementary Figure S3 from Promotion of Colorectal Cancer Invasion and Metastasis through Activation of NOTCH–DAB1–ABL–RHOGEF Protein TRIO Open
Supplementary Fig. S3 shows that Rho promotes transendothelial migration (TEM) of CRC cells.
View article: Supplementary Figure S2 from Promotion of Colorectal Cancer Invasion and Metastasis through Activation of NOTCH–DAB1–ABL–RHOGEF Protein TRIO
Supplementary Figure S2 from Promotion of Colorectal Cancer Invasion and Metastasis through Activation of NOTCH–DAB1–ABL–RHOGEF Protein TRIO Open
Supplementary Fig. S2 shows Knockdown of DAB1 mRNA inhibits metastasis whereas its induction enhances metastasis.
View article: Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S4 with its legend on page 2
View article: Supplementary Figure S3 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S3 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S3 with its legend on page 2
View article: Supplementary Figure S5 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S5 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Supplementary Figure S5
View article: Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S1.
View article: Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors Open
Suppl. Fig. S1.